Guardant Health, Inc.
For the period ended Mar 31, 2025. Filed Apr 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 30, 2025
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| OPERATING ACTIVITIES: | ||
| Net loss | $(95,159) | $(114,985) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 10,236 | 10,712 |
| Operating lease costs | 7,870 | 7,619 |
| Gain on extinguishment of convertible notes | (13,672) | — |
| Stock-based compensation | 37,757 | 27,041 |
| Unrealized losses on marketable equity securities | — | 30,054 |
| Impairment of non-marketable equity securities | 5,000 | — |
| Interest income received on marketable debt securities | 7,677 | — |
| Other | 940 | 1,408 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (6,115) | 4,220 |
| Inventory, net | (6,173) | (1,042) |
| Prepaid expenses and other current assets, net | (3,072) | (5,627) |
| Other assets, net | 697 | 1,024 |
| Accounts payable and accrued liabilities | (1,537) | 13,240 |
| Operating lease liabilities | (9,565) | (8,835) |
| Deferred revenue | 2,427 | 4,887 |
| Net cash used in operating activities | $(62,689) | $(30,284) |
| INVESTING ACTIVITIES: | ||
| Maturities of marketable debt securities | $307,323 | $35,000 |
| Purchases of property and equipment | (4,459) | (6,934) |
| Net cash provided by investing activities | $302,864 | $28,066 |
| FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock upon exercise of stock options | $768 | $213 |
| Employee taxes paid related to settlement of restricted stock units | (15,497) | (1,544) |
| Repurchase of treasury stock | (45,010) | — |
| Payment of debt issuance costs | (12,138) | — |
| Proceeds from unwinding of convertible note hedges | 5,030 | — |
| Other | (3) | 257 |
| Net cash used in financing activities | $(66,850) | $(1,074) |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 773 | (1,138) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 174,098 | (4,430) |
| Cash, cash equivalents and restricted cash—Beginning of period | 629,755 | 1,133,687 |
| Cash, cash equivalents and restricted cash—End of period | $803,853 | $1,129,257 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $698,572 | $1,029,027 |
| Restricted cash | 105,281 | 100,230 |
| Total cash, cash equivalents and restricted cash | $803,853 | $1,129,257 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.